Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
CIPLA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CIPLA Mar-23 |
ADCOCK INGRAM Jun-14 |
CIPLA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,185 | 316 | - | |
Low | Rs | 852 | 228 | - | |
Sales per share (Unadj.) | Rs | 281.9 | 94.0 | - | |
Earnings per share (Unadj.) | Rs | 35.1 | -23.7 | - | |
Cash flow per share (Unadj.) | Rs | 49.7 | -19.6 | - | |
Dividends per share (Unadj.) | Rs | 8.50 | 0 | - | |
Avg Dividend yield | % | 0.8 | 0 | - | |
Book value per share (Unadj.) | Rs | 289.2 | 73.8 | - | |
Shares outstanding (eoy) | m | 807.15 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.6 | 2.9 | 124.9% | |
Avg P/E ratio | x | 29.0 | -11.5 | -252.5% | |
P/CF ratio (eoy) | x | 20.5 | -13.9 | -148.1% | |
Price / Book Value ratio | x | 3.5 | 3.7 | 95.5% | |
Dividend payout | % | 24.2 | 0 | - | |
Avg Mkt Cap | Rs m | 822,164 | 45,919 | 1,790.5% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 38,301 | 2,882 | 1,329.0% | |
Avg. sales/employee | Rs Th | 0 | 3,696.8 | - | |
Avg. wages/employee | Rs Th | 0 | 671.3 | - | |
Avg. net profit/employee | Rs Th | 0 | -931.5 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 227,531 | 15,870 | 1,433.7% | |
Other income | Rs m | 5,121 | 111 | 4,608.1% | |
Total revenues | Rs m | 232,653 | 15,982 | 1,455.8% | |
Gross profit | Rs m | 48,079 | -2,750 | -1,748.2% | |
Depreciation | Rs m | 11,721 | 685 | 1,711.2% | |
Interest | Rs m | 1,095 | 430 | 254.8% | |
Profit before tax | Rs m | 40,384 | -3,754 | -1,075.8% | |
Minority Interest | Rs m | 0 | -10 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 12,029 | 235 | 5,128.0% | |
Profit after tax | Rs m | 28,355 | -3,999 | -709.1% | |
Gross profit margin | % | 21.1 | -17.3 | -121.9% | |
Effective tax rate | % | 29.8 | -6.2 | -476.7% | |
Net profit margin | % | 12.5 | -25.2 | -49.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 168,051 | 11,624 | 1,445.8% | |
Current liabilities | Rs m | 50,333 | 6,540 | 769.6% | |
Net working cap to sales | % | 51.7 | 32.0 | 161.5% | |
Current ratio | x | 3.3 | 1.8 | 187.9% | |
Inventory Days | Days | 73 | 111 | 66.1% | |
Debtors Days | Days | 7 | 124 | 5.3% | |
Net fixed assets | Rs m | 117,318 | 6,775 | 1,731.5% | |
Share capital | Rs m | 1,614 | 74 | 2,190.8% | |
Net worth | Rs m | 233,460 | 12,457 | 1,874.2% | |
Long term debt | Rs m | 0 | 4,377 | 0.0% | |
Total assets | Rs m | 290,067 | 23,531 | 1,232.7% | |
Interest coverage | x | 37.9 | -7.7 | -489.7% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.8 | 0.7 | 116.3% | |
Return on assets | % | 10.2 | -15.2 | -66.9% | |
Return on equity | % | 12.1 | -32.1 | -37.8% | |
Return on capital | % | 17.8 | -19.8 | -89.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 32,377 | 1,355 | 2,390.0% | |
From Investments | Rs m | -23,885 | -416 | 5,742.4% | |
From Financial Activity | Rs m | -9,583 | 3,973 | -241.2% | |
Net Cashflow | Rs m | -968 | 4,912 | -19.7% |
Compare CIPLA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare CIPLA With: WYETH SMS LIFESCIENCES INDIA NATCO PHARMA TORRENT PHARMA SYSCHEM (I).
Asian markets traded higher on Tuesday following overnight gain on Wall Street.